On October 15, 2021 Bristol Myers Squibb reported The UK National Institute for Health and Care Excellence (NICE) has recommended it’s (BMS) Opdivo (nivolumab) as a treatment option for certain resected oesophageal or gastro-oesophageal junction (GEJ) patients (Press release, Bristol-Myers Squibb, OCT 15, 2021, View Source [SID1234591277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Opdivo has been cleared as an adjuvant treatment of completely resected oesophageal or GEJ cancer in adults who have residual disease following neoadjuvant chemoradiotherapy.

Изображение химической структуры
Opdivo
The recommendation was made based on clinical trial evidence showing that, for people who had residual disease after chemoradiotherapy and following surgery, Opdivo increases the time individuals’ live without their cancer returning compared to placebo.

In a statement, NICE added that Opdivo is likely to be more effective at extending how long people live overall, although the clinical trial evidence to demonstrate this is not yet available.

According to BMS, there are around 200 people in England who are eligible for this treatment. The company has also agreed a commercial agreement which makes Opdivo available to the NHS with a discount.

The main two types of oesophageal cancer are squamous cell carcinoma and adenocarcinoma – squamous cell carcinoma typically affects the upper and middle oesophagus, while adenocarcinoma usually affects the lower oesophagus, including the gastro-oesophageal junction.